dailypharmkorea

LOGIN

ID PW
MemberShip
2026-04-04 01:51:27

검색

Dailypharm Live Search Close

Policy
29 new drugs with 45 ingredients reimb this year
by Lee, Tak-Sun Dec 31, 2024 05:55am
This year, 45 new drugs with 29 ingredients were listed for reimbursement benefits under Korea’s health insurance. Among them, the only homegrown new drug was 'Zastaprazan citrate', a P-CAB-based gastroesophageal reflux disease treatment. As of the 30th, 45 new drugs were listed for reimbursement in Korea’s National health insurance system from January to December 2024, improving patient access. In January alone, five 5 drugs were reimbursed, including the anti-cancer drugs ‘Braftovi Cap,’ and ‘Bosulif Tab,’ ulcerative colitis treatment ‘Zeposia Cap,’ asthma and COPD treatment ‘Trimbow Inhaler,’ and neurofibromatosis treatment ‘Koselugo Cap.’ In February, two new drugs, ‘Kerendia Tab’ for chronic kidney disease and ‘Luxturna Inj’ for inherited retinal dystrophy, were approved, followed by ‘Trelegy 200 Elllipta Inhaler’ for asthma in March. In April, four new drugs were covered by health insurance, including cytomegalovirus treatment ‘Livtencity Tab,’ plaque psoriasis treatment ‘Sotyktu Tab,’ and anticancer drugs ‘Poteligeo Inj,’ and ‘Enhertu Inj.’ In May, the atopic dermatitis treatment ‘Adtralza Prefilled Syringe’ and the iron deficiency treatment ‘Ferrinject Inj’ were covered, and in June, morning sickness treatment ‘Diclectin Enteric-coated Tab’ were covered for the first time under the government's health insurance program. New Drugs reimbursed in 2024 in Korea, (number of items) New drug approvals continued into the second half of the year. In July, 3 new drugs were introduced, including the eosinophilic asthma treatment ‘Fasenra Prefilled Syringe,’ the hemophilia treatment ‘Idelvion Inj,’ and the anti-cancer drug ‘Xpovio Tab.’ In August, the CAPS treatment ‘Ilaris Inj’ and schizophrenia and bipolar disorder treatment ‘Latuda Tab’ were listed. No new drugs were listed in September, but five came out at once in October. The glaucoma treatment ‘Rhopressa Eye Drops,’ secondary hyperparathyroidism treatment ‘Orkedia Tab,’ the domestic new drug GERD treatment ‘Jaqbo Tab,’ COVID-19 treatment ‘Paxlovid Tab’ and ‘Veklury Inj’ were covered by health insurance, reducing the financial burden on the patients. In November, ‘Empaveli Inj,’ a treatment for paroxysmal nocturnal hemoglobinuria, was added to the list, and in December, new drugs such as ‘Vyxeos Liposome Inj,’, a treatment for acute myeloid leukemia, ‘Qarziba,’ a treatment for neuroblastoma, and ‘Camzyos Cap,’ a treatment for obstructive hypertrophic cardiomyopathy, were added to the reimbursement list. Of the new drugs on the list, 12 were covered by risk-sharing agreements, which accounts for more than 40% of the total listed items. Ten drugs accepted the average price of alternative drugs and skipped insurance price cap negotiations and only negotiated on the estimated claim amount. Next January, apremilast, an ingredient used for psoriatic arthritis and psoriasis, will be reimbursed for the first time. The five drugs that will be reimbursed are all generics. The original apremilast-based drug was Amgen's Otezla Tab, but it failed to gain reimbursement and was withdrawn from the Korean market. This is the first time that a group of domestic generic companies have entered Korea’s health insurance reimbursement market.

< 151 152 153 154 155 156 157 158 159 160 >

Online newspaper registration number : Seoul 아 52715 Date of registration : November 20, 2019
Publisher-Editor : Lee Jeong Seok Executive Editor : Ga In Ho
Address : 401-ho,A-dong, 128, Beobwon-ro, Songpa-gu, Seoul, Korea
Tel : 82-2-3473-0833 | Fax : 82-2-3474-0169
Youth Protection Policy : Kang Sin Kook | Contact : unkindfish@dailypharm.com for more information
Copyright ⓒ Dailypharmkorea 1999-2025,All rights reserved.